Phase IV Study of rhGH Injection in Adult Short Bowel Syndrome

This is a multicenter, open-label, single-arm clinical trial. A total of 100 participants with short bowel syndrome (SBS) receiving parenteral nutrition (PN) support are planned to be enrolled. The trial includes a 2-week run-in phase and a 4-week intervention phase, during which participants will receive rhGH injections. A safety follow-up period will then be conducted through Week 52.

NCT Number	NCT07691125
Lead Sponsor	Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions	Short Bowel Syndrome (SBS) in Adults
Enrollment	100 participants
Start Date	2024-07-31
Primary Completion	2027-04-28 (estimated)
Study Completion	2028-06-10 (estimated)
Updated on ClinicalTrials.gov	2026-07-08